Look out Dupixent, Lilly’s lebrikizumab is on the marchEli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic Share XLook out Dupixent, Lilly’s lebrikizumab is on the marchhttps://pharmaphorum.com/news/look-out-dupixent-lillys-lebrikizumab-is-on-the-march/
Almirall kicks off another hunt for skin disease therapy partnershipsSpanish drugmaker Almirall has launched another search for early-stage research projects that it can partner in dermatology, its Share XAlmirall kicks off another hunt for skin disease therapy partnershipshttps://pharmaphorum.com/news/almirall-kicks-off-another-hunt-for-skin-disease-therapy-partnerships/
Almirall names Nazzi as new CEO after Guenter leaves for MerckSpanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to Share XAlmirall names Nazzi as new CEO after Guenter leaves for Merckhttps://pharmaphorum.com/news/almirall-names-nazzi-as-new-ceo-after-guenter-leaves-for-merck/
Almirall, Happify partner on digital tool for psoriasis mental healthIt’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases Share XAlmirall, Happify partner on digital tool for psoriasis mental healthhttps://pharmaphorum.com/news/almirall-happify-partner-on-digital-tool-for-psoriasis-mental-health/
Popit and Almirall’s new app tracks adherence to psoriasis medFinnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken Share XPopit and Almirall’s new app tracks adherence to psoriasis medhttps://pharmaphorum.com/news/popit-and-almiralls-new-app-tracks-adherence-to-psoriasis-med/
Novartis takes $485m hit after axing eczema drug from pipelineNovartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Share XNovartis takes $485m hit after axing eczema drug from pipelinehttps://pharmaphorum.com/news/novartis-takes-485m-hit-after-axing-eczema-drug-from-pipeline/
Plug and Play aims to accelerate Almirall’s digital start-upsAlmirall has announced a partnership with Plug and Play, a health tech accelerator and innovation platform, to boost Share XPlug and Play aims to accelerate Almirall’s digital start-upshttps://pharmaphorum.com/news/plug-and-play-aims-to-accelerate-almiralls-digital-start-ups/
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and Share XAlmirall strikes option deal to buy Bioniz and dermatology drug BNZ-1https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/
How big pharma and startups can learn from each otherFrancesca Wuttke’s varied career has taken her from research roles to private equity and now to the role Share XHow big pharma and startups can learn from each otherhttps://deep-dive.pharmaphorum.com/magazine/digital-health/almriall-startups-francesca-wuttke-digital/
